In a 2022 study titled "Assessment of In Vitro Immunostimulatory Activity of an Adjuvanted Whole-Cell Inactivated Neisseria gonorrhoeae Microparticle Vaccine Formulation," researchers investigated whether this bacterium responsible for gonorrhea could trigger the CD95 death receptor on antigen-presenting cells (APCs) in vitro.

The study revealed uncertainty about N. gonorrhea's ability to induce CD95 expression. To address this, experiments were conducted, showing a dose-dependent induction of CD95 in APCs exposed to adjuvanted gonococci microparticles (MP). This suggests N. gonorrhoeae can induce CD95 expression on APCs, raising questions about its impact on immune responses.

In summary, the 2022 research demonstrated that Neisseria gonorrhoeae could trigger the CD95 death receptor in APCs, potentially affecting adaptive immune responses. You can read the full article as the source of my answer at: https://www.mdpi.com/2076-393X/10/7/983.